Literature DB >> 19171106

The use of opioids in the treatment of osteoarthritis: when, why, and how?

Jeremy L R Goodwin1, Jan J Kraemer, Zahid H Bajwa.   

Abstract

As life expectancy increases every decade, the incidence and prevalence of osteoarthritis (OA) also will increase. Despite progress in our knowledge of the pathophysiology of OA, the management of OA-mediated pain continues to challenge physicians. Concern regarding the cardiovascular effects of cyclooxygenase-2 inhibitors and the gastrointestinal and renal side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in general has limited the use of these medications in the management of chronic non-cancer pain. Appropriately dosed and monitored use of opioids for OA pain, when more conservative methods have failed, has potentially fewer life-threatening complications associated with it than the more commonly and often less successfully employed pharmacotherapeutic approaches to care. When used as part of a multimodal approach to pain control, opioids are a safe and effective treatment for joint pain, including that of OA. Patients for whom NSAIDs are contraindicated, or for whom combined acetaminophen, tramadol, and NSAID therapy is ineffective, may be started on low-dose opioids and titrated as needed and tolerated. Patient education and informed consent, exercise, complementary medicine, and the use of a controlled substance agreement increases the likelihood of patient compliance with treatment guidelines, improving functional capacity and quality of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171106     DOI: 10.1007/s11926-009-0002-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  28 in total

1.  Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center.

Authors:  Niels Becker; Annemarie Bondegaard Thomsen; Alf Kornelius Olsen; Per Sjøgren; Per Bech; Jørgen Eriksen
Journal:  Pain       Date:  1997-12       Impact factor: 6.961

2.  Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers.

Authors:  T Rygnestad; K Zahlsen; F A Samdal
Journal:  Eur J Clin Pharmacol       Date:  2000-05       Impact factor: 2.953

Review 3.  Drug abuse, dependence, and addiction in chronic pain patients.

Authors:  D A Fishbain; H L Rosomoff; R S Rosomoff
Journal:  Clin J Pain       Date:  1992-06       Impact factor: 3.442

4.  Update of ACR guidelines for osteoarthritis: role of the coxibs.

Authors:  Thomas J Schnitzer
Journal:  J Pain Symptom Manage       Date:  2002-04       Impact factor: 3.612

Review 5.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Tramadol: a new centrally acting analgesic.

Authors:  K S Lewis; N H Han
Journal:  Am J Health Syst Pharm       Date:  1997-03-15       Impact factor: 2.637

7.  Positive effect of patient education for hip surgery: a randomized trial.

Authors:  Janine-Sophie Giraudet-Le Quintrec; Joël Coste; Laurent Vastel; Véronique Pacault; Luc Jeanne; Jean-Paul Lamas; Luc Kerboull; Martine Fougeray; Christian Conseiller; André Kahan; Jean-Pierre Courpied
Journal:  Clin Orthop Relat Res       Date:  2003-09       Impact factor: 4.176

8.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

9.  A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery.

Authors:  James R Fricke; Rezaul Karim; Donna Jordan; Norman Rosenthal
Journal:  Clin Ther       Date:  2002-06       Impact factor: 3.393

Review 10.  Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials.

Authors:  W Zhang; A Jones; M Doherty
Journal:  Ann Rheum Dis       Date:  2004-03-05       Impact factor: 19.103

View more
  5 in total

1.  Association of Tramadol Use With Risk of Hip Fracture.

Authors:  Jie Wei; Nancy E Lane; Marcy B Bolster; Maureen Dubreuil; Chao Zeng; Devyani Misra; Na Lu; Hyon K Choi; Guanghua Lei; Yuqing Zhang
Journal:  J Bone Miner Res       Date:  2020-02-05       Impact factor: 6.741

2.  Association of tramadol with risk of myocardial infarction among patients with osteoarthritis.

Authors:  J Wei; M J Wood; M Dubreuil; G Tomasson; M R LaRochelle; C Zeng; N Lu; J Lin; H K Choi; G Lei; Y Zhang
Journal:  Osteoarthritis Cartilage       Date:  2019-10-16       Impact factor: 6.576

Review 3.  Narcotics in rheumatology.

Authors:  Mahsa Tehrani; Mathia Aguiar; James D Katz
Journal:  Health Serv Insights       Date:  2013-06-13

4.  Long-term opioid use and mortality in patients with chronic non-cancer pain: Ten-year follow-up study in South Korea from 2010 through 2019.

Authors:  In-Ae Song; Hey-Ran Choi; Tak Kyu Oh
Journal:  EClinicalMedicine       Date:  2022-07-18

5.  Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Cannabinoids for Chronic Pain: Protocol for a Systematic Review.

Authors:  Mohammed M Mohiuddin; Glenio Mizubuti; Simon Haroutounian; Shannon Smith; Fiona Campbell; Rex Park; Ian Gilron
Journal:  JMIR Res Protoc       Date:  2019-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.